Cizzle Biotechnology sets date for Annual General Meeting

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer of early cancer tests, announces that the Company’s notice of Annual General Meeting has been posted to shareholders and will shortly be available for viewing on the Company’s website at https://cizzlebiotechnology.com.

The Annual General Meeting will be held at 11:00 a.m. on Tuesday 16 June 2026 at the offices of Shakespeare Martineau LLP, C/O Ampa Holdings LLP, Level 19, The Shard, 32 London Bridge Street, London, United Kingdom, SE1 9SG.

Share on:

Written by: Amilia Stone

Find more news, interviews, share price & company profile here for:
Cizzle Biotechnology Holdings plc

Latest Company News

Cizzle Biotechnology raises £500,000 to support US lung cancer test adoption

October 26, 2026

Cizzle Biotechnology has conditionally raised £500,000 from existing shareholder Frazer Lang to support the commercial adoption of its CIZ1B lung cancer blood test in the USA and progress UK partner agreements, including with the NHS.

Cizzle Biotechnology to present CIZ1B lung cancer test advances at SYNLAB Symposium

October 23, 2026

Cizzle Biotechnology will present improvements to its CIZ1B lung cancer biomarker test at the SYNLAB Innovation Academy Symposium on 5 November 2026, highlighting technical evaluation work with the Christie Pathology Partnership and peer-reviewed research demonstrating test accuracy and reproducibility.

Cizzle Biotechnology gains recognition for lung cancer test

October 19, 2026

Cizzle Biotechnology has been shortlisted for Best Non-Therapeutic R&D Company of the Year at the One Nucleus Genesis Conference, recognising progress with its CIZ1B biomarker test for early-stage lung cancer.

Cizzle Biotechnology revises US payments as lung cancer test rollout advances

October 15, 2026

Cizzle Biotechnology has agreed revised payment terms with Cizzle Bio Inc, deferring US$1.81 million in guaranteed advance payments to December 2027 while converting advance royalties into upfront or milestone payments.

Cizzle Bio outlines clinical use and ordering process for CIZ1B lung cancer blood test

October 14, 2026

Cizzle Bio has outlined clinical applications and ordering procedures for its CIZ1B lung cancer blood test, which is available through licensed healthcare providers in two Texas metropolitan areas.

Cizzle blood test enters US clinical use

October 7, 2026

The US launch moves Cizzle from development and validation into commercialisation, with the company now focused on increasing access to the test and building demand among healthcare providers.

Cizzle Biotechnology sets date for Annual General Meeting

We’ll keep you in the loop!

Latest Company News

Search

Follow us on Social Media: